Humacyte, Inc. (HUMA) vs TuHURA Biosciences, Inc. (HURA)

Humacyte, Inc. and TuHURA Biosciences, Inc. are both Biotechnology companies. Humacyte, Inc. and TuHURA Biosciences, Inc. are of similar size ($122.1M and $116.6M). TuHURA Biosciences, Inc. has the higher net margin (0.00% vs −4,448.9%) and the higher return on invested capital (−74.2% vs −433.7%). Across the 14 metrics below, TuHURA Biosciences, Inc. leads on 9 and Humacyte, Inc. on 5.

Valuation

Metric HUMA HURA Biotechnology median
P/E n/m n/m 8.50
P/S 47.48 n/m 9.71
P/B 3.22 6.25 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 40.30 n/m 9.21
Earnings yield (113.95%) (30.34%) (33.15%)
Free cash flow yield (96.88%) (26.29%) (25.50%)

Profitability

Metric HUMA HURA Biotechnology median
Gross margin (494.58%) 0.00% 65.16%
Operating margin (5,240.78%) 0.00% 0.00%
Net margin (4,448.89%) 0.00% 0.00%
Free cash flow margin (4,599.72%) 0.00% 0.00%
Return on equity (534.42%) (163.84%) (56.36%)
Return on assets (68.16%) (92.31%) (48.04%)
Return on invested capital (433.66%) (74.20%) 0.00%

Growth

Metric HUMA HURA Biotechnology median
Revenue growth (TTM) 149.82% — 6.02%
EPS growth (last fiscal year) 79.37% 47.93% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HUMA HURA Biotechnology median
Debt to equity 2.07 0.47 0.00
Current ratio 6.21 0.18 4.72
Net debt to EBITDA (0.12) 0.12 0.96

Dividend

Metric HUMA HURA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric HUMA HURA Biotechnology median
Market cap 122.09m 116.62m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack